Sales of Lilly’s popular tirzepatide drugs, Mounjaro for type II diabetes and Zepbound for obesity disappointed ... The GLP-1 ...

In an unusual move, the U.S. Food and Drug ... recent classification by the IARC also does not imply that beverages and foods ...

Try virtual yoga, study suggests The new study focused on almost 15,000 adult volunteers who were given activity trackers to ...

A lack of education about the impacts of military service on hormone ... Leonard Pogach, M.D., executive director for ...

Use of these drugs can improve diabetes management without increasing risk for hypoglycemia (hypoglycemia is not strictly ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

A pioneering clinical ... Popular Diabetes and Weight-Loss Drug May Reduce Risk of Alzheimer's Disease Oct. 24, 2024 — Researchers have found that semaglutide may lower the risk of Alzheimer's ...

Endocrinologic and Metabolic Drugs Advisory Committee, the majority of panel members voted against the approval of sotagliflozin (Zynquista™) for use as an adjunct to insulin therapy for glycemic ...

Elevated IL-10 in diabetes causes capillary obstruction, linked to cognitive deficits. Blocking IL-10 receptors shows promise for improving brain function.

For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over a 1-year period.

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini ...